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Subclinical thyroid disorders: significance and
clinical impact
Salman Razvi,1,2 Jolanta U Weaver,1,3 Simon H S Pearce2,4
ABSTRACT
Subclinical thyroid diseases are defined by abnormal
serum thyroid stimulating hormone (TSH) levels
associated with normal thyroid hormone concentrations.
The diagnosis of these conditions depends on defining
the ‘normal’ euthyroid TSH range; in this review,
arguments for and against lowering the upper limit of
TSH are summarised. Although, subclinical
hypothyroidism and subclinical hyperthyroidism are
frequently encountered, their long-term consequences
are debated due to conflicting results from many
observational studies. The causes, effects and outcomes
of treatment of both subclinical diseases are described,
and the direction of future research in these conditions is
outlined.
INTRODUCTION
Thyroid disorders are the second most common
endocrine condition after diabetes mellitus; thus it
is not surprising that each year 25% of the popu-
lation have their thyroid function tests checked at
an estimated cost of £30 million in the UK.1
The hypothalamicepituitaryethyroid axis is
regulated via a classic control loop: thyroid
hormones (triiodothyronine (T3) and thyroxine
(T4)) mediate the feedback loop of thyroid stimu-
lating hormone (TSH) and thyroid releasing
hormone (TRH) and determine the TSH set point
for any given individual. A decrease of T4 or T3
leads to an increase in TSH as both hormones, T3
directly and T4 indirectly, contribute to hypotha-
lamic and pituitary T3 levels via intra pituitary/
cerebral conversion of T4 to T3. There is a linear
relation between thyroid hormones and log TSH
concentration reflecting that TSH is a sensitive
indicator of thyroid status.
With highly sensitive and specific assays,
increased frequency of testing and heightened
awareness of subclinical conditions we are now able
to detect ever more subtle degrees of thyroid
dysfunction: non-thyroidal disease, subclinical
hypothyroidism and subclinical hyperthyroidism.
The increased frequency of thyroid testing and the
ageing population is leading to more abnormal
results being detected and can pose a challenge for
clinicians and biochemists in its interpretation and
clinical applications.
DEFINITION OF SUBCLINICAL THYROID
CONDITIONS AND SERUM TSH REFERENCE
RANGE
The subclinical states can be defined as normal
serum levels of thyroid hormones in the presence of
either elevated serum TSH (subclinical hypothy-
roidism or SHypo) or low/undetectable TSH
concentrations (subclinical hyperthyroidism or
SHyper). Thus, the diagnosis is based solely on the
biochemical abnormality of serum TSH levels, and
hence the normal range for serum TSH levels needs
to be established. This task is proving to be quite
challenging, especially defining the upper limit of
the normal TSH reference range. This is because of
a number of factors. First, it is important to note
that circulating TSH displays two types of varia-
tions: pulsatile secretion with intervals between 1 h
and 2 h, the amplitude of which is affected by
fasting, surgery and illness,2e4 and circadian
rhythm characterised by the surge of TSH before
the onset of sleep. Thus the time of phlebotomy is
important, because even in a healthy individual, the
TSH level varies throughout the day, with early
morning values greater than later ones, and is
accentuated by sleep deprivation, strenuous exer-
cise, or working during the night or evening shifts.
Thus repeated measurements in the same indi-
vidual may vary considerably over months. Second,
other factors such as non-thyroidal illness or preg-
nancy may affect serum TSH as well as thyroid
hormone levels. Finally, exogenous factors such as
certain medications (amiodarone, lithium, gluco-
corticoids, anticonvulsants, etc) and iodine intake
also influence thyroid function.
The reference TSH levels are generally derived
from the 2.5th to 97.5th centile of individuals
without evidence of thyroid dysfunction, positive
thyroid antibodies, or medications affecting thyroid
function.5 The limitation of this approach is that
some individuals may have cytological evidence of
lymphocytic infiltration while being negative for
thyroid antibodies.6 Thus TSH levels have a skewed
distribution at higher concentrations in healthy
populations suggesting that some healthy people
with subclinical disease are included in the upper
limit of the reference range.7 8 For instance, inclusion
of antibody-positive subjects significantly increases
TSH 97.5th centile levels.8 The NHANES III survey
in the USA measured TSH levels in non-pregnant
people (n¼13 344) aged 12 years or older, who were
not on any medications known to affect thyroid
hormone metabolism, and who had negative anti-
thyroid peroxidase (TPO) antibodies; in this popu-
lation, the reference range of TSH concentration
(2.5the97.5th centile) was 0.45e4.12 mIU/l, with
a median value of 1.4 mIU/l.9
There has been a debate whether the upper limit
of the reference range for serum TSH should be
reduced. The improved sensitivity and specificity of
current antibody-based immunometric assays,
together with improvement in thyroid antibody
tests used for pre-screening subjects over the last
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20 years, has led to a steady decline of the upper reference limit
for TSH from about 10 mIU/l to approximately 4.0e4.5 mIU/l.
The follow-up study of the Whickham cohort has found that
individuals with a serum TSH >2.0 mIU/l at their primary eval-
uation had an increased OR of developing hypothyroidism over
the next 20 years, especially if thyroid antibodies were present.10
An increased risk for hypothyroidism was even seen in antibody-
negative subjects with a TSH over 2.0 mIU/l. It is likely that
a proportion of such subjects had low levels of thyroid antibodies
that could not be detected by the insensitivemicrosomal antibody
agglutination tests used in the initial study.11 Even the current
sensitive anti-TPO immunoassaysmaynot identify all individuals
with low-grade thyroid autoimmunity. In the future, it is possible
that the upper limit of the serum TSH euthyroid reference range
may be reduced to 2.5 mIU/l because>95% of rigorously screened
normal euthyroid volunteers have serum TSH values between
0.4 mIU/l and 2.5 mIU/l.5 There are data indicating that African
Americans, who have a very low incidence of Hashimoto
thyroiditis, have a mean TSH level of 1.18 mIU/l, which strongly
suggests that this value is the true normal mean for a normal
population.12 The American Association of Clinical Endocrinol-
ogists has recommended that the TSH upper limit should be
3.0 mIU/l.13 On the other hand, it has been argued that there is no
evidence for associated adverse outcomes in people with TSH
values between 2.50 mIU/l and 4.0 mIU/l and that some of these
TSH levels may be due to technical reasons with the TSH assay
(abnormal TSH isoforms and heterophile antibodies).14 The
variability of the TSH upper limit reported for different popula-
tions may be related to variance in hidden thyroid pathology,
sampling time of day, TSH and antibody assay characteristics. In
particular, data fromUKquality assessment schemes indicate that
TSH reference ranges quoted by diagnostic companies (and
adopted by many laboratories) were not related to assay bias.15
More recently it has been confirmed that 50%of cases of abnormal
TSH levels are normalised on repeat testing,16 thus introducing an
additional challenge to interpretation of TSH results.
Finally, TSH reference intervals are population dependent and
assay dependent, and statistical methodology dependent. We
provide the example of three neighbouring hospitals that could
provide care to one individual patient. There was a difference in
reference range between three of them, potentially giving the
patient a different diagnosis depending which hospital
performed thyroid function tests (TFTs) (table 1). Hospitals
1 and 2 use the same assay (ElectroChemiLuminescence
immunoassay; Roche Diagnostics, Burgess Hill, UK) but have
adopted different reference ranges. The third hospital uses
a similar assay but manufactured by Siemens.
SUBCLINICAL HYPOTHYROIDISM
Aetiology
The commonest cause for SHypo is usually inadequately treated
hypothyroidism. In two large studies, about a third of individ-
uals on thyroxine were noted to have abnormal TSH levels.9 17
The other common causes of SHypo are autoimmune thyroiditis
(Hashimoto disease) and previously treated thyroid disease. The
causes of SHypo and elevated serum TSH levels are outlined in
table 2. It is important to differentiate between SHypo and
other reasons for a raised TSH level; SHypo should be confirmed
by repeat tests after 3e6 months, at which time transiently
raised TSH levels (eg, caused by non-thyroidal illness) will have
normalised.
Prevalence
The prevalence of SHypo has been noted to be between 4% and
20% depending on the gender and the age of the population
studied. In the Whickham survey, SHypo (TSH >6.0 mIU/l)
was prevalent in 7.5% of women and 2.8% of men.11 In the
much larger NHANES III study in the USA, the prevalence of
SHypo (TSH >4.6 mIU/l) was 4.3% of the population; this
reduced to 3.9% when individuals with thyroid disease or posi-
tive thyroid antibodies were excluded.9 This study also showed
that subclinical thyroid diseases are more prevalent in white and
MexicaneAmerican populations than in African Americans.
Furthermore, analysis of the NHANES III data also showed that
serum TSH levels increased with age and in women; individuals
aged between 12 years and 39 years were less likely to have
elevated serum TSH levels (z2%) compared with age groups
60e69 years (z7%) and 80+ years (z14%). The large Colorado
Health Fair study found the prevalence of SHypo to be much
higher at 8.5%, but it was not strictly population-based; the
sample was recruited from health fair visitors and included
individuals on medications affecting thyroid function.17 Never-
theless, the age-related and gender-related increases in prevalence
of elevated serum TSH were also detected in this study. As
discussed above, it is quite probable that serum TSH concen-
trations increase progressively with age even in healthy indi-
viduals, thus the prevalence of SHypo may be being
overestimated.18 Therefore, there is a need to investigate
whether age-specific TSH reference ranges would provide better
decision making and improved patient outcomes.
Implications of SHypo
Progression of disease
The risk of progression of SHypo to overt hypothyroidism is
based on the level of TSH, age, female sex as well as positive
thyroid antibody status. In the 20-year follow-up of the
Whickham study, the annual rate of progression to overt
Table 1 Thyroid function test reference ranges in three neighbouring
hospitals
Thyroid function test Hospital 1* Hospital 2y Hospital 3z
TSH (mU/l) 0.4e4.0 0.30e3.82 0.3e4.7
Free T4 (pmol/l) 9e25 12.0e22.0 9.5e21.5
Free T3 (pmol/l) 2.8e7.5 3.1e6.8 3.5e6.5
*American Thyroid Association guidelines (2002).
yRoche assay reference range.
zSeimens assay reference range.
TSH, thyroid stimulating hormone; T3, triiodothyronine; T4, thyroxine.
Table 2 Causes of SHypo and raised TSH levels
Causes Details
Autoimmune hypothyroidism Usually associated with positive thyroid
autoantibodies and/or hypoechogenic
appearance on ultrasound
Previously treated thyroid
or neck disease
History of radioiodine or surgical treatment
Drugs Lithium, amiodarone, anticonvulsants
(due to increased T4 metabolism),
interferon, sunitinib
Inadequate treatment
of thyroid disease
Non-compliance, undertreatment with
thyroid hormones, malabsorption, interaction
with other substances (iron, calcium);
overtreatment with antithyroid drugs
Transiently raised TSH levels Non-thyroidal illness (recovery phase)
Systemic diseases with
thyroid involvement
Sarcoidosis, amyloidosis, lymphoproliferative
disorders, haemochromatosis
TSH receptor gene mutations Several loss of function gene mutations
have been found in non-autoimmune SHypo
Pituitary tumours secreting
low bioactivity TSH
SHypo, subclinical hyperthyroidism; TSH, thyroid stimulating hormone; T4, thyroxine.
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hypothyroidism was 4.3% in women who had raised TSH as
well as positive thyroid autoantibodies, 3% if TSH alone was
raised, and 2% for those with positive thyroid autoantibodies
only.10 Other studies have reported similar results.19 20
Conversely, the rate of spontaneous normalisation of elevated
serum TSH is also well recognised. In a prospective study of
patients with SHypo aged 55 years or more, nearly 40%
normalised their TSH values, of which 67% normalised in the
first 2 years of follow-up.21 In an observational study using the
computerised database of a large healthcare organisation, a one-
off raised TSH level between 5.6 mIU/l and 10 mIU/l normalised
in 62% of patients, whereas levels higher than 10 mIU/l
normalised in 27% of patients.16 There is evidence that increased
frequency of testing and the lower limit of the T4 reference
range influence patients being categorised as SHypo or euthy-
roid.22 In that study of 21 patients with SHypo confirmed on
two occasions prior to inclusion, and who went on to have
monthly thyroid function tests for 13 months, 29% of partici-
pants remained in SHypo state on all visits, while 67% had
variable diagnosis ranging from euthyroid, SHypo and overt
hypothyroidism. In summary, individuals with a single raised
TSH level should not be classed as being SHypo and should be
monitored after 3e6 months. In individuals who normalise their
TSH levels, further monitoring up to a year after the index test
may be appropriate.
Symptoms and quality of life
Most patients found by screening to have subclinical hypothy-
roidism have at least one symptom that could be related to this
diagnosis.23 Symptoms include muscle cramps, dry skin, intol-
erance to cold, constipation, poor energy levels, fatigue and
mental slowness. Baseline data in people with SHypo from
a study by Cooper et al showed an increased prevalence of
hypothyroid symptoms.24 The Colorado cross-sectional study of
25 862 participants reported increased prevalence of hypothyroid
symptoms in response to a validated survey. The 2336 subjects
who were identified as having SHypo, more often reported
having dry skin, poor memory, slow thinking, muscle weakness,
fatigue, muscle cramps, cold intolerance, puffy eyes, constipa-
tion, and voice hoarseness than did euthyroid subjects.17 It is
important to note that, whereas euthyroid subjects experienced
a mean of 12.1% of all listed symptoms, overtly hypothyroid
subjects had 16.6% of these symptoms (p<0.05 versus euthyroid
group), and subjects with SHypo reported an intermediate
13.7% of the symptoms (p<0.05 versus euthyroid group). This
suggests a ‘dosage effect’ between the degree of thyroid failure
and symptoms. Consistent with these findings, a Swiss study
involving 332 women with hypothyroidism reported that 24%
of the 93 subjects with mild thyroid failure exhibited typical
symptoms of hypothyroidism.25 Another study that compared
SHypo patients with age-matched and gender-matched UK
general population found that all scales of the health status
questionnaire SF-36 were reduced; this finding was consistent
with reduced health.26 Some experts have argued that these are
not population-based studies and that some studies have also
included people with undertreated hypothyroidism.7 Other
cross-sectional studies have demonstrated evidence of specific
neurobehavioral and neuromuscular dysfunction in patients
with SHypo. Depression,27 memory loss,28 cognitive impair-
ment29 and a range of neuromuscular complaints30 have been
reported to occur more frequently in patients with this condi-
tion. The only cross-sectional study that stratified individuals by
TSH levels noted significantly altered ankle reflex times and
myoglobin levels only in those patients with TSH higher than
12 mIU/l.31 The association of SHypo with psychiatric disorders
has also not been consistent. Many such reports are hindered by
not controlling for the effects of age, gender, inpatient hospi-
talisation and use of lithium on the prevalence of elevated TSH
levels. Additionally, the mere association between SHypo and
psychiatric disorders should not lead to the conclusion that
SHypo brings about these associated disorders. The four large
epidemiological studies that examined cognitive and affective
scores in SHypo subjects found few32 33 or no34 35 significant
differences overall, and none in those with TSH between 5 mIU/l
and 10 mIU/l.
Cardiovascular risk and mortality
The association of SHypo with cardiovascular (CV) disease has
been quite controversial. One of the earliest caseecontrol studies
showed a strong association between SHypo (as defined by
exaggerated response to thyrotropin releasing hormone) and
angiographically demonstrated coronary artery disease.36 Since
then, there have been several community-based cross-
sectional37e43 and longitudinal studies37 39 41e46 that have
assessed this relationship. However, there has been no large-scale
randomised controlled trial of treatment of SHypo in assessing
CV disease. The cross-sectional component of the Rotterdam
study demonstrated a twofold excess of myocardial infarction
and aortic atherosclerosis in SHypo women aged 55 years or
more, with a vascular risk attributable to Shypo comparable
with that associated with diabetes mellitus, smoking and
hypercholesterolaemia.37 However, the longitudinal component
of this study (follow-up period of 4.6 years), did not demon-
strate this association, but this may have lacked power as total
CV events were quite low. The cross-sectional Whickham study
showed a weak association between minor ECG changes and
SHypo in women, independent of other variables.38 A 20-year
follow-up study of the cohort did not reveal an association
between autoimmune thyroid disease and CV disease.44 But
many patients with SHypo in the original survey received L-
thyroxine replacement therapy and the analysis did not differ-
entiate between SHypo and euthyroid people with positive
antibodies. A Japanese study showed that SHypo was associated
with prevalent CV disease and incident all-cause mortality
independent of all other variables in men but not in women.39 A
longitudinal caseecontrol study, in Birmingham, UK, of 1191
people aged more than 60 years followed-up for 10-years,
showed no increased risk of CV disease in the group with
SHypo, although it did not differentiate between treated and
untreated patients.45 Similarly, the prevalence of CV disease was
not increased in SHypo patients in a cross-sectional survey of
3410 elderly people in Maryland, USA.43 However, a cross-
sectional study in New Mexico, USA, of a randomly selected
sample of 112 people aged 65 years or more, found that there
was an increased prevalence of CV disease in participants whose
TSH was >10 mIU/l.40
A recent study, with cross-sectional and longitudinal arms, of
people aged between 70 years and 79 years reported no associa-
tion between SHypo and CV disease at baseline, but there was
an increased incidence of congestive heart failure after 4 years of
follow-up in the moderate and severe SHypo groups (TSH
7e9.9 mIU/l and >10 mIU/l, respectively), but not in the mild
SHypo group.41 Another recent study that had cross-sectional
and longitudinal arms (follow-up of 20 years) found a significant
association of CV disease at baseline as well at follow-up.42 On
the other hand, the Leiden study of people aged 85 years or more
showed that an elevated TSH was associated with a decreased
risk of death from CV disease during 4 years of follow-up.46
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Thus, there have been a number of cross-sectional as well as
longitudinal studies that have assessed the risk of ischaemic
heart disease (IHD) in people with SHypo, with varying results.
The differences in results are quite likely to be due to the
different population samples studied (inclusion or exclusion of
subjects with history of thyroid disease, previous CV event,
current L-thyroxine therapy) as well as variations in definitions
of IHD, length of follow-up and varying limits of TSH cut-off
values that defined SHypo. The most likely cause of the differ-
ence, however, is likely to be due to the age groups of the SHypo
patients studied: younger patients are more likely to have an
increased IHD risk compared with older patients.47
Pregnancy
The prevalence of SHypo in pregnancy is 2.3%.48 49 This relative
thyroid hormone deficiency can affect maternal and fetal
outcomes. Several poor outcomes have been reportedwith SHypo
on the mother, including increased fetal death50 and increased
maternal hypertension.51 The fetus does not develop secretion
from its own thyroid gland until 12 weeks of gestation and is
partially reliant on maternal thyroid hormones until
18e20 weeks gestation. Thyroid hormones are essential for fetal
neurodevelopment and inadequate maternal thyroid hormones
have an adverse impact on the child’s intelligence quotient.52
Furthermore, Pop et al showed that children born tomothers with
lower serumT4 levelswithin the normal reference range andwith
normal serum TSH levels had lower psychomotor development
indices at 10 months of age compared with women with higher
T4 levels.53 Those authors termed this condition of low normal
T4 levels as ‘relative hypothyroxinaemia’. These studies suggest
that SHypo as well as lower thyroid hormones during early
pregnancy has an adverse outlook on fetal as well as maternal
outcomes. This then warrants the question: should all pregnant
women be screened for thyroid abnormality during early preg-
nancy?TheAmericanThyroid Association states that there is not
enough evidence to justify screening for all pregnant women but
suggests that women at risk of thyroid disease should have their
thyroid function measured.7 However, a recent study showed
that this strategy could potentially miss up to a third of women
with SHypo.54 Therefore, it is essential that thyroid function,
when measured and found to be abnormal, is treated during
pregnancy for optimal maternal and fetal well-being.
Effects of treatment
The potential benefits and risks of treating SHypo have been
debated for a few decades. The possible advantages are prevention
of progression to overt hypothyroidism, reversal of symptoms of
hypothyroidism and improvement of quality of life, and
a potentially decrease in CVevents and mortality. There has been
no randomised controlled trial (RCT) that has investigated the
effect of L-thyroxine on CV disease incidence. There have been
a number of studies that have looked at various surrogate CV risk
factors. RCTs of L-thyroxine in SHypo show that the effect of
L-thyroxine on serum lipids is variable.24 55e62 The variability
arises due to the differing nature and number of patients recruited,
study design and dose of L-thyroxine therapy. Previous meta-
analysis has shown that reduction in total cholesterol ranges from
0.2 mmol/l to 0.4 mmol/l, and low-density lipoprotein choles-
terol by 0.26 mmol/l.63 64 There has been no reported beneficial
effect on high-density lipoprotein cholesterol or triglycerides.
There have also been studies investigating the effect of
L-thyroxine on cardiac function that have shown a beneficial
effect.24 55 65e72 A few trials that studied endothelial dysfunction
found that L-thyroxine had a beneficial effect.56 73
Several randomised, prospective, placebo-controlled trials of L-
thyroxine therapy in SHypo published so far, have assessed
symptoms of hypothyroidism or health status.24 35 55e59 Cooper
et al24 and Nystrom et al55 reported significant improvements in
symptoms of hypothyroidism. Jaeschke and colleagues did not
find any improvement in health status (general or disease
specific) in their patients with SHypo, apart from some
improvement in a composite psychometric memory score.57
That study has been criticised because of insufficient treatment
of the SHypo patientsdthe mean TSH levels of the treated
patients were 4.61 mIU/l. Meier and colleagues concluded that
physiological mean L-thyroxine replacement therapy in people
with SHypo (the mean TSH at baseline in this group was
12.1 mIU/l at baseline) improves clinical symptoms of hypo-
thyroidism.59 On the other hand, Kong et al did not find any
significant improvement in their patients with mild SHypo, in
terms of symptom scores. In fact, there was a significant
worsening in anxiety scores on L-thyroxine therapy.58 The
patients in this study were not recruited by population screening
and did not have stable SHypo, and had a rigid dosing regimen
(50 mg/day or 100 mg/day) leading to a treated TSH level of
3.4 mIU/l (towards upper limit of normal range). Two recent
studies came to the opposite conclusions: one found no signifi-
cant improvement in symptoms or other psychological param-
eters after L-thyroxine therapy,35 whereas our group found
a significant improvement in certain parameters of a disease-
specific quality of life questionnaire.56
The effects of L-thyroxine on cognitive function and memory
are not clear. Some studies have shown a beneficial effect
whereas others have not.27 28 35 55 57
One of the most important reasons for the conflicting results
in all the trials listed above could be the small sample size. As
seen above from the Colorado study, people with mild TSH
elevations are likely to have fewer symptoms than those with
higher TSH levels. This would mean that a higher sample size
would be required to show a significant improvement after
intervention. In other words, it would be easier to detect
a significant difference in a smaller sample if the degree of
thyroid failure was higher as compared with when the failure
was relatively mild and subtler. For example, in the trial by
Meier and colleagues, subgroup analysis failed to show signifi-
cant improvement in symptoms in people with TSH less than
12 mIU/l (n¼18).59 This fact was amply illustrated in the largest
RCT to date (n¼100) that showed significant improvements in
lipid levels and quality of life even in patients with mild SHypo
(TSH <10 mIU/l).56
In the USA, a consensus statement of three societies
concluded that there was no evidence that routine treatment of
SHypo should be recommended in patients with serum TSH
levels below 10 mIU/l.7 The societies sponsoring the consensus
statement disagreed with this recommendation and recommend
treatment of mild SHypo.74 A clinically reasonable position is
that individuals with Shypo and TSH <10 mU/l can be offered
a 3-month or 4-month trial of T4 therapy if they have symp-
toms suggestive of hypothyroidism; the decision about contin-
uation of T4 depending upon symptomatic benefits.75
SUBCLINICAL HYPERTHYROIDISM
Definition
SHyper is defined as a serum TSH that is below the reference
range, with free T3 and free T4 concentrations within the
reference range (table 3). There is an important distinction
within SHyper, related to whether the serum TSH is low
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(0.1e0.4 mU/l) or completely suppressed to <0.1 mU/l or
<0.05 mU/l. The former pattern of results (grade I SHyper) is
typical of non-thyroidal illness or drug effects and not consistent
with endogenous hyperthyroidism; some individuals with the
latter pattern of investigations (suppressed TSH: grade II
SHyper) will have endogenous hyperthyroidism. By definition,
many individuals with SHyper do not have symptoms, although
weight loss, anxiety, tremulousness and palpitations are occa-
sionally seen.
Aetiology
In more than half of cases, a single reduced serum TSH
measurement will revert to within the reference range on
a repeat test.76 Of individuals with a sustained reduction in
serum TSH, the commonest cause for SHyper is overtreated
hypothyroidism. However other (non-thyroid hormone) drugs
may lower TSH, including commonly prescribed oral opiates (eg,
tramadol), glucocorticoids, levodopa, amiodarone and iodine-
containing CT scan contrast media. Non-thyroidal systemic
illness, which may take many forms, may lead to an isolated
reduction or complete suppression of the serum TSH concen-
tration (either grade I or II SHyper). An isolated reduction in
serum TSH is also commonly found as a normal feature of the
first trimester of pregnancy, as well as in extreme old age.77
Lastly, a few people have mild but true endogenous hyperthy-
roidism as the cause of their low TSH, reflecting overproduction
of thyroid hormones generally owing to indolent toxic multi-
nodular goitre or mild Graves disease (box 1).
Prevalence
SHyper affects about fivefold fewer people than subclinical
hypothyroidism. TheNHANESIII survey found that 1%of people
between the ages of 60 years and 80 years had subclinical hyper-
thyroidism, as defined by a serum TSH <0.4 mU/l on a single
blood test. In people above the age of 80 years, the prevalence rose
to 3%.9 Three quarters of individuals with SHyper have a serum
TSH that is low (0.1e0.4 mU/l), and the remainder, about
0.3e1% of unselected populations, have a suppressed TSH
concentration (below 0.1 mU/l). Due to the transient nature of
SHyper, these numbers are likely to over-represent the prevalence,
and the number of individuals with sustained SHyper is likely to
be substantially lower than this. There is a slight preponderance of
women, (women:men 1.5:1). In our hospital-based series, the
average age was 77 years.
Implications of SHyper
Progression
The risk of progression to overt hyperthyroidism is largely
dependent upon serum TSH concentration and aetiology. Indi-
viduals with Graves disease are more likely to progress. In Grade
I SHyper, the risk of progression is low.76 However, if the TSH is
suppressed to below 0.1 mIU/l, the risk of progression to overt
thyrotoxicosis is between 2% and 5% per year.7
Cardiovascular risk and mortality
Data from Framingham show that an undetectable TSH
concentration (<0.1 mU/l) is associated with a threefold
increase in the risk of subsequent atrial fibrillation.78 Similarly,
the atrial fibrillation prevalence was doubled in individuals with
SHyper in the Cardiovascular Health Study, examining patients
older than 65 years over 13 years of follow-up.43 Retrospectively
acquired data from an acute general hospital setting show that
there is almost no difference in the atrial fibrillation rate in overt
thyrotoxicosis compared with that found in SHyper.79 A 10-year
observational study of patients over 60 years old from
Birmingham, UK, also demonstrated that all-cause mortality
was excessive in patients with the lowest quintile of TSH,
predominantly due to circulatory (cardiovascular and cerebro-
vascular) mortality in the first 5 years of follow-up.45 In this
important community-based survey, circulatory deaths were
maximal (2.3-fold excess; 95% CI 1.3 to 4.0) after 5 years of
observation, with a circulatory mortality of 25% in the group
with a TSH <0.5 mU/l, compared with 15% in the group with
normal TSH.45 Similarly, the prospective Leiden ‘85-plus’ study
confirmed that the excess mortality associated with a low TSH
extends right across the range of elderly subjects, with an
increased risk of cardiovascular mortality over 4 years of follow-
up in these subjects: a sex-adjusted HR of 1.5 (95% CI 1.0 to
2.1) per SD decrease in serum TSH.46 Nevertheless, this has not
been the conclusion of all studies, particularly those examining
younger population cohorts.42 A recently published meta-
analysis of eight studies that examined mortality with rela-
tionship to thyroid status showed that there was an overall
HR for mortality of 1.4 (95% CI 1.1 to 1.8) in SHyper cohorts
as compared with euthyroid groups.80 Thus, SHyper should, at
least, be considered as a marker for circulatory disease and
adverse outcome.
Bone mass, fracture risk, muscle function and dementia
In addition to the association with adverse vascular outcomes,
SHyper is also associated with several other degenerative prob-
lems. Many studies show a reduced bone mineral density (BMD)
Table 3 Degrees of hyperthyroidism
Overt
hyperthyroidism
T3
thyrotoxicosis
Grade
II SHyper
Grade I
SHyper
TSH (reference
range 0.4e4.0 mIU/l)
<0.1 <0.1 <0.1 0.1e0.4
Free T4 High Normal Normal Normal
Free T3 High High Normal Normal
SHyper, subclinical hyperthyroidism; TSH, thyroid stimulating hormone; T3,
triiodothyronine; T4, thyroxine.
Box 1 Causes of subclinical hyperthyroidism
ENDOGENOUS CAUSES
< Toxic multinodular goitre
< Solitary, autonomous follicular adenoma
< Graves disease
EXOGENOUS (NON-THYROIDAL) CAUSES
< Treatment with levothyroxine, tri-iodothyronine or dessicated
thyroid extract
< Other drugs, for example, levodopa, amiodarone, glucocorti-
coids, opiates
< Administration of iodine-containing intravenous contrast agents
< Non-thyroidal illness (sick euthyroid syndrome)
< Pregnancy
< Old age (>80 years)
RARE CAUSES
< Pituitary disease
< Tumour human chorionic gonadotropin secretion
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in post-menopausal women with SHyper compared with
euthyroid controls,81 82 though the effects of exogenous
subclinical hyperthyroidism are less clear.83 Importantly, a large
population-based study has demonstrated an increase risk of hip
and lumbar spine fracture in SHyper individuals.84 Furthermore,
increased tendency to falls due to decreased muscle strength
might compound fracture risk in individuals with SHyper.85
Dementia has been linked with low TSH levels in some
studies. The Rotterdam Study found that participants with
reduced baseline TSH levels but normal FT4 levels had a relative
risk of 3.5 of developing dementia.86 Another study that
analysed TSH levels in patients with dementia found that
decreased or borderline TSH values were associated with an
increased probability of having vascular dementia.87 However,
a large cross-sectional study found no association of low TSH
with cognitive state when the confounders of co-morbidity and
medications were taken into account.88
Effects of treatment
The effects of treatment on the long-term outcome of SHyper
are largely unknown. There have been three small controlled
trials of treatment of SHyper, with BMD as the main outcome
indicator.89e91 The first study used radioiodine in a non-rando-
mised fashion in 16 postmenopausal women with SHyper.89
BMD at the spine and hip was significantly better in the radi-
oiodine-treated women compared with the untreated group,
largely because of the continued decline in BMD in the
untreated individuals. The second study randomised 16 post-
menopausal women with endogenous grade II SHyper to
methimazole treatment or placebo.90 BMD at distal radius was
improved in the active treatment group by the second year of
the study. Last, a beneficial effect of methimazole was found on
non-invasive indices of cardiac function and on BMD in seven
Italian women with SHyper compared with placebo-treated
subjects.91 Overall, these studies provide little evidence to guide
practice in individuals with SHyper, and a case by case approach
has to be taken. Surveys of UK and North American thyroi-
dologists have shown that many do treat individuals with
SHyper, with atrial fibrillation being a strong indication for
treatment, but with goitre, reduced BMD and symptoms as
additional factors.92 93
CONCLUSION
Subclinical thyroid disorders are very common, being more
prevalent than diabetes. Despite this, there is no clear consensus
of how these disorders should be managed due to conflicting
results from various observational studies and a real lack of good
randomised treatment studies examining hard endpoints or
important outcomes. For SHypo, the available evidence so far
suggests that treatment of these disorders should be considered
if the TSH abnormality is persistent, if the person is less than
65 years old and has symptoms compatible with hypothy-
roidism. For SHyper, atrial fibrillation is a strong indicator to
treat. In the presence of sinus rhythm, individuals with persis-
tent grade II SHyper, with symptoms, goitre or osteoporosis,
should be considered for treatment. Randomised controlled trials
of treatment are required to provide good evidence on effects of
long-term cardiovascular and mortality outcomes to guide
practice.
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